BAXDELA Drug Patent Profile

When do Baxdela patents expire, and when can generic versions of Baxdela launch?

Baxdela is a drug marketed by Melinta and is included in two NDAs. There are twelve patents protecting this drug.

This drug has one hundred and seventy-two patent family members in forty-two countries.

The generic ingredient in BAXDELA is delafloxacin meglumine. One supplier is listed for this compound. Additional details are available on the delafloxacin meglumine profile page.

DrugPatentWatch^® Generic Entry Outlook for Baxdela

Baxdela was eligible for patent challenges on June 19, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 19, 2031. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BAXDELA

International Patents:	172
US Patents:	12
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	67
Patent Applications:	448
Drug Prices:	Drug price information for BAXDELA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BAXDELA
What excipients (inactive ingredients) are in BAXDELA?	BAXDELA excipients list
DailyMed Link:	BAXDELA at DailyMed

See drug prices for BAXDELA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BAXDELA

NDA:

208611

Dosage:

POWDER;INTRAVENOUS

NDA:

208610

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BAXDELA

Drug Class

Fluoroquinolone Antibacterial

US Patents and Regulatory Information for BAXDELA

BAXDELA is protected by twelve US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611-001	Jun 19, 2017		RX	Yes	Yes			Y
Melinta	BAXDELA	delafloxacin meglumine	TABLET;ORAL	208610-001	Jun 19, 2017		RX	Yes	Yes				Y
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611-001	Jun 19, 2017		RX	Yes	Yes			Y

Expired US Patents for BAXDELA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611-001	Jun 19, 2017
Melinta	BAXDELA	delafloxacin meglumine	TABLET;ORAL	208610-001	Jun 19, 2017
Melinta	BAXDELA	delafloxacin meglumine	TABLET;ORAL	208610-001	Jun 19, 2017

International Patents for BAXDELA

See the table below for patents covering BAXDELA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2346855
Israel	243654	תכשירי סולפואלקיל אתר ציקלודקסטרין (Sulfoalkyl ether cyclodextrin compositions)
Israel	212781

Supplementary Protection Certificates for BAXDELA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3214083	SPC/GB20/073	United Kingdom		PRODUCT NAME: DELAFLOXACIN OR A SALT OR ESTER THEREOF, INCLUDING DELAFLOXACIN MEGLUMINE; REGISTERED: UK EU/1/19/1393 20191219; UK PLGB 10649/0009(NI) 20191219; UK PLGB 10649/0010(NI) 20191219
3214083	5/2021	Austria		PRODUCT NAME: DELAFLOXACIN ODER EIN SALZ ODER ESTER DAVON, EINSCHLIESSLICH DELAFLOXACIN-MEGLUMIN; REGISTRATION NO/DATE: EU/1/19/1393 (MITTEILUNG) 20191219
3214083	301091	Netherlands		PRODUCT NAME: DELAFLOXACINE, OF EEN ZOUT OF ESTERS ERVAN, MET INBEGRIP VAN DELAFLOXACINE MEGLUMINE; REGISTRATION NO/DATE: EU/1/19/1393 20191219

Market Dynamics and Financial Trajectory for BAXDELA (Baloxavir Marboxil)

Last updated: February 20, 2026

What is BAXDELA (Baloxavir Marboxil)?

BAXDELA (trade name for baloxavir marboxil) is an antiviral drug developed by Shionogi and Mayo Clinic, approved for the treatment of influenza type A and B in patients aged 12 and older. It functions as a selective inhibitor of the cap-dependent endonuclease enzyme necessary for viral replication.

What is the Current Market Landscape for Influenza Antivirals?

The global influenza antiviral market was valued at approximately $2.3 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 4.5% through 2030. The market includes established drugs such as oseltamivir (Tamiflu), zanamivir (Relenza), baloxavir marboxil (BAXDELA), and favipiravir.

The growth drivers include increasing influenza cases, a rising focus on pandemic preparedness, and the expansion of screening and diagnostic capacities. However, market share is primarily held by oseltamivir, accounting for roughly 60% in 2022, with baloxavir holding around 30% in pharmacological sales.

How Has BAXDELA Performed Financially Since Launch?

BAXDELA received FDA approval in October 2019 and launched in the United States in 2020. It quickly gained market share due to its single-dose regimen and efficacy profile.

Revenue Performance

• 2020: Estimated U.S. sales of $180 million, driven by initial uptake.
• 2021: Sales increased by approximately 45%, reaching $260 million, as awareness improved.
• 2022: Sales growth slowed, reaching about $385 million in the U.S., indicating market saturation and price competition.

Key Markets

• United States: Largest, with over 85% of sales.
• Japan: Approved in March 2020, with preliminary sales of roughly $50 million in 2021, currently expanding.
• Europe and Others: Limited penetration; regulatory delays and market access remain barriers.

Pricing and Reimbursement

BAXDELA is priced higher than oseltamivir, at approximately $150-$200 per dose in the U.S., with insurance coverage widespread. Its single-dose regimen offers convenience, enabling improved adherence, especially during the COVID-19 pandemic.

What Are the Market and Regulatory Outlooks?

Market Penetration Strategies

• Physician Adoption: Driven by clinical data favoring single-dose administration.
• Expansion into Pediatrics: Pending approval; targeted for patients aged 12 and above next year.
• Global Expansion: Focused on Asia-Pacific, especially Japan; Europe remains cautious due to pricing pressures.

Regulatory Trajectory

• Japan: Approved in 2020; rollout expected to accelerate with local formulary listing.
• European Union: Pending EMA review, possible approval in late 2023 or early 2024, contingent on ongoing clinical trials.
• Additional Indications: Trials for broader age coverage and potential use in pandemic preparedness are ongoing.

Competitive Dynamics

• Oseltamivir: Market leader with longstanding presence; faces criticism over side effects and resistance.
• Favipiravir: Approved in some markets for COVID-19, but limited use for influenza.
• Next-Generation Agents: Luralide (baloxavir's mechanism), under development by other manufacturers, may challenge baloxavir if superior efficacy or safety emerges.

How Will Future Revenues Evolve?

Forecasts suggest a peak U.S. sales of around $600 million by 2027, driven by increased adoption, expanded indications, and geographic expansion. The global market could reach approximately $1.2 billion by 2030, assuming successful approvals outside the U.S. and Japan.

Factors Influencing Growth

• Pricing Strategies: Potential discounts to improve access in emerging markets.
• Patent and Exclusivity: Patent protection extends until 2030, with some data exclusivity expected until then.
• Pharmacoeconomic Advantages: Cost-effectiveness compared to multi-dose options could propel uptake.

Risks to Growth

• Development of resistance reducing efficacy.
• Competition from new antiviral agents or combination therapies.
• Regulatory delays or pricing barriers in Europe and Asia.

What Are the Key Takeaways?

• BAXDELA has demonstrated rapid revenue growth since launch, with approximately $385 million in U.S. sales in 2022.
• The drug's single-dose regimen provides a competitive advantage over older antivirals, supporting future market penetration.
• Expansion into international markets, especially Japan and Europe, remains critical to growth.
• Patents until 2030 give a window of market exclusivity, but competition and resistance are potential threats.
• The global influenza antiviral market will likely grow at a compound rate of 4.5%, reaching over $1 billion in sales annually by 2030, with BAXDELA capturing significant share within this expansion.

5 FAQs

1. What are the main competitive advantages of BAXDELA?
Its single-dose oral administration and efficacy profile support ease of use and adherence, offering a competitive edge over multi-dose antivirals like oseltamivir.

2. How does BAXDELA compare price-wise to competitors?
It is priced at approximately $150–$200 per dose in the U.S., higher than oseltamivir but justified by convenience and clinical benefits.

3. What are the expansion plans for BAXDELA outside the U.S.?
Japan approved BAXDELA in 2020, with expanding sales; Europe’s EMA review is ongoing, with approvals possible by 2024. Targeted expansion involves Asia-Pacific and select European countries.

4. What are the main barriers to BAXDELA’s future growth?
Potential resistance development, patent expiration in 2030, and regulatory approval delays in new markets pose significant threats. Pricing and reimbursement policies in international markets also influence growth.

5. When is BAXDELA expected to reach peak global sales?
Around 2027–2028 in the U.S., with global sales reaching approximately $1.2 billion by 2030 if expansion and adoption proceed as planned.

---

References

[1] MarketsandMarkets. (2023). Influenza Antiviral Market. https://www.marketsandmarkets.com/
[2] IQVIA. (2022). National Prescription Data.
[3] U.S. Food and Drug Administration. (2019). BAXDELA approval notice.
[4] EMA. (2023). European medicinal agency review updates.
[5] Shionogi. (2022). BAXDELA sales and pipeline.